Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open Label, Randomized, Parallel-group Study of Efficacy and Safety of Eculizumab (JSC GENERIUM, Russia) vs. Soliris® (Alexion Pharma GmbH, Switzerland) in Patients With Paroxysmal Nocturnal Hemoglobinuria

NCT04463056 is registered in ClinicalTrials.gov with AO GENERIUM as lead sponsor.

NCT NCT04463056
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04463056 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open Label, Randomized, Parallel-group Study of Efficacy and Safety of Eculizumab (JSC GENERIUM, Russia) vs. Soliris® (Alexion Pharma GmbH, Switzerland) in Patients With Paroxysmal Nocturnal Hemoglobinuria
Lead sponsor
AO GENERIUM
Phase
Phase 3
Overall status
Completed
Start date
November 29, 2017
Completion date
October 16, 2018
Enrollment
32 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

marchiafava-micheli syndrome, paroxysmal hemoglobinuria, paroxysmal nocturnal hemoglobinuria